What was known before {#section22-2054358118813088}
=====================

Curcumin, a component of the spice turmeric, has anti-inflammatory and anti-fibrotic properties. Animal models and small-scale human studies suggest that curcumin may slow the progression of chronic kidney disease.

What this adds {#section23-2054358118813088}
==============

By randomizing at least 500 patients with albuminuric chronic kidney disease to 90 mg per day of micro-particle curcumin or placebo, we will determine its effects on albuminuria and renal function. This trial will also determine the need for, and the feasibility of, a large-scale trial to assess clinically meaningful end points.

Introduction {#section24-2054358118813088}
============

Chronic kidney disease (CKD) is defined by an estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73 m^2^ or evidence of persistent kidney damage, such as excessive albuminuria. CKD is associated with significant morbidity and mortality but the most important complication of CKD is the progression to kidney failure (end-stage renal disease, ESRD). Patients who progress to ESRD require dialysis or transplantation to survive. They experience numerous complications, have high mortality rates,^[@bibr1-2054358118813088]^ and their care is very expensive.^[@bibr2-2054358118813088]^ Therefore, preventing or slowing the progression from CKD to ESRD is an important clinical and research goal. Currently, few treatments have been proven to slow progression, and even when these therapies are appropriately applied, many patients still progress to ESRD.^[@bibr3-2054358118813088]^ This may be explained in part by inflammation and fibrosis, 2 processes that play a role in the progression of CKD,^[@bibr4-2054358118813088],[@bibr5-2054358118813088]^ but are not addressed by current therapies.

Curcumin, a component of the dietary spice turmeric, has proven anti-inflammatory and anti-fibrotic properties ([Supplement Figure S1](http://journals.sagepub.com/doi/suppl/10.1177/2054358118813088)) and has been shown to mitigate renal damage in multiple animal models of CKD ([Supplement Table S1](http://journals.sagepub.com/doi/suppl/10.1177/2054358118813088)).^[@bibr6-2054358118813088][@bibr7-2054358118813088][@bibr8-2054358118813088]-[@bibr9-2054358118813088]^ The ability of curcumin to reduce albuminuria in humans is supported by 2 trials in patients with nephrotic-range proteinuria.^[@bibr10-2054358118813088][@bibr11-2054358118813088]-[@bibr12-2054358118813088]^ However, these trials were small and patients were treated with turmeric, of which curcumin is only a small component. Furthermore, curcumin in its traditional form has very poor bioavailability.^[@bibr13-2054358118813088][@bibr14-2054358118813088]-[@bibr15-2054358118813088]^ To increase patients' exposure to curcumin, we chose to study a micro-particle formulation that is 27 times more bioavailable.^[@bibr16-2054358118813088]^

Micro-particle curcumin for the treatment of CKD-1 (MPAC-CKD-1) is a double-blind, placebo-controlled randomized trial that will measure the effect of micro-particle curcumin on 6-month changes in 2 important markers of CKD progression: albuminuria and eGFR. Positive effects in either of these markers will justify a larger, international trial that will determine micro-particle curcumin's ability to decrease the risk of ESRD in patients with CKD.

Methods {#section25-2054358118813088}
=======

This protocol is presented according to the SPIRIT guidelines (see [supplemental materials](http://journals.sagepub.com/doi/suppl/10.1177/2054358118813088)).^[@bibr17-2054358118813088]^

Study Setting {#section26-2054358118813088}
-------------

We will coordinate this trial through the Lilibeth Caberto Kidney Clinical Research Unit at London Health Sciences Centre in London, Ontario. The trial steering committee is comprised of AX Garg and MA Weir, who will also provide outcome and adverse event adjudication. We will identify patients through 3 clinics in London, Ontario, Canada, and 1 clinic in Hamilton, Ontario, Canada. In each clinic, attending physicians will introduce the study and interested patients will meet with research coordinators to discuss the trial in detail. Those who are eligible and willing to participate will provide written, informed consent prior to randomization.

Eligibility Criteria {#section27-2054358118813088}
--------------------

We will recruit patients with advanced CKD but who have not yet progressed to an irreparable stage. We will enroll patients with an eGFR between 15 and 60 mL/min/1.73 m^2^ and overt albuminuria, defined by a 24-hour urine collection with more than 300 mg of protein or a random urine albumin-to-creatinine ratio greater than 30 mg/mmol (265.2 mg/g). We will exclude patients with conditions that may potentially be exacerbated by the use of micro-particle curcumin (active peptic ulcer disease, hepatobiliary disease, history of significant bleeding) or who take medications that may interact with micro-particle curcumin ([Table 1](#table1-2054358118813088){ref-type="table"}).

###### 

Inclusion and Exclusion Criteria.

![](10.1177_2054358118813088-table1)

  ------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------
  Inclusion criteria                                                                                      18 years of age and older
  Chronic kidney disease (eGFR 15 to 60 mL/min/1.73 m^2^)                                                 
  Albuminuria (24-hour urine protein ⩾300 mg, or urinary albumin-to-creatinine ratio ⩾30 mg/mmol)         
  For those with diabetes mellitus, willing to measure and record blood glucose concentrations            
  Stable dose of ACE inhibitor or ARB                                                                     
  Exclusion criteria                                                                                      Life expectancy \<1 year
  Renal replacement therapy in the prior 3 months                                                         
  Plans for renal transplantation during the study period                                                 
  Active peptic ulcer disease                                                                             
  Recent hepatobiliary disease                                                                            
  Evidence of recent acute kidney injury (\>50% increase in serum creatinine in the preceding 30 days)    
  Significant bleeding history in the last 6 months                                                       Gastrointestinal bleed or retroperitoneal bleed requiring transfusion, or intracranial hemorrhage
  Ongoing use of drugs that may interact with curcumin                                                    Oral anticoagulants
  Chemotherapeutic agents: cyclophosphamide, camptothecin, mechlorethamine, or doxorubicin                
  Anti-psychotic medications: haloperidol, aripiprazole, risperidone, ziprasidone, pimozide, quetiapine   
  Allergy to turmeric or its derivatives (ginger, cumin, cardamom)                                        
  Allergy to components of the investigational product                                                    
  ------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------

*Note.* eGFR = estimated glomerular filtration rate; ACE = angiotensin converting enzyme; ARB = angiotensin receptor blocker.

Interventions {#section28-2054358118813088}
-------------

We will randomly assign patients to receive either micro-particle curcumin or matching placebo. Micro-particle curcumin will be administered at 90 mg per day (three 30 mg capsules once daily) for 6 months. Our rationale for the dosage selection is presented in the [supplemental materials](http://journals.sagepub.com/doi/suppl/10.1177/2054358118813088). The dose will remain constant over the study period. Randomization to micro-particle curcumin or matching placebo will occur in a 1:1 ratio. Balanced block randomization will be conducted using a computerized algorithm with variable block sizes and treatment allocation will be stratified by site (3 sites in London, 1 site in Hamilton) and by baseline diabetes mellitus status. After providing written informed consent, patients will be allocated randomly by means of a 24-hour online computerized system to maintain allocation concealment. Participants, investigators, and all research staff will remain unaware of the treatment allocation. Unblinding will occur in the setting of a severe adverse reaction in which the treating physician believes the investigational product may have a role in the patient's condition or treatment.

Concomitant Care {#section29-2054358118813088}
----------------

Hypertension and proteinuria will be managed according to the Canadian Hypertension Education Program guidelines,^[@bibr18-2054358118813088]^ which suggest treatment with an angiotensin-converting-enzyme inhibitor or an angiotensin receptor blocker. Patients not taking one of these medications require the reason why to be documented in the medical record. The doses of these medications may be reduced or the drug may be stopped during the course of the study, but the medical indication prompting that decision (eg, hyperkalemia) must be documented. We will not impose dietary restrictions because dietary sources of curcumin provide exceedingly small amounts of curcumin^[@bibr19-2054358118813088],[@bibr20-2054358118813088]^; however, we will ask patients to refrain from using over-the-counter curcumin or turmeric supplements and document any use at each study visit.

Outcomes {#section30-2054358118813088}
--------

### Primary outcomes {#section31-2054358118813088}

We will assess the 6-month change in 2 co-primary outcomes: the change in albuminuria, and the change in eGFR. Albuminuria will be measured using albumin-to-creatinine ratios from first morning urine samples. The eGFR will be calculated using the CKD-EPI formula, which includes patient age, sex, race (African or non-African), and the serum creatinine concentration.^[@bibr21-2054358118813088]^

### Secondary outcomes {#section32-2054358118813088}

#### Glycemic control {#section33-2054358118813088}

We will assess glycemic control using the percentage of glycated hemoglobin at baseline, 3 months, and 6 months among patients with diabetes mellitus (diabetes mellitus was a stratification variable in the randomization). Curcumin use has been associated with improved glycemic control in animal models,^[@bibr22-2054358118813088]^ and human studies.^[@bibr23-2054358118813088]^

#### Study agent discontinuation and safety {#section34-2054358118813088}

Because MPAC-CKD-1 may inform the launch of subsequent larger trial, a better understanding of the tolerability of micro-particle curcumin in the CKD population is necessary. We will test protocol compliance through pill counts and interviews at each follow-up visit. Side effects will be assessed using standardized case report forms at each visit.

#### Renal failure composite (eGFR loss of ⩾30%, or ESRD, or death) {#section35-2054358118813088}

We expect less than 10% of participants will experience these outcomes by 6 months. Although we will not have adequate statistical power to detect a meaningful effect of curcumin on these outcomes, we will document any trends to inform the expected event rate for future studies. We will define ESRD as an eGFR \<15 mL/min/1.73 m^2^ or the initiation of renal replacement therapy, which includes dialysis or transplantation.

#### Health-related quality of life {#section36-2054358118813088}

We will compare health-related quality of life scores determined by the RAND version of the Short Form-36 (SF-36) questionnaire administered at baseline and 6 months. We will compare changes in both the physical composite score and the mental composite score. Beyond preservation of kidney function are several other potential mechanisms by which curcumin may benefit quality of life, including potential benefits on depression and chronic pain.^[@bibr24-2054358118813088],[@bibr25-2054358118813088]^

### Additional outcomes {#section37-2054358118813088}

#### Serum curcumin levels {#section38-2054358118813088}

The strength of previously identified relationships between traditional curcumin exposure and clinical outcomes has been limited by the difficulty in achieving measurable serum curcumin levels. To confirm the improved bioavailability reported with micro-particle curcumin,^[@bibr16-2054358118813088]^ and to strengthen any relationship between micro-particle curcumin and any outcomes we identify, we will measure serum trough levels of curcumin and its major metabolites in the first 25 participants randomized.^[@bibr14-2054358118813088]^

Recruitment {#section39-2054358118813088}
-----------

To ensure we can achieve this recruitment goal, we have assessed the number of provisionally eligible patients managed in the 4 clinics involved in this trial and have gauged the success of a recently conducted trial with similar inclusion criteria.^[@bibr26-2054358118813088],[@bibr27-2054358118813088]^ In addition, we have worked closely with research coordinators to remove possible barriers to enrollment and streamline the data collection process.

![Participant timeline.\
*Note.* eGFR = estimated glomerular filtration rate; SF-36 = Short Form-36; UACR = urinary albumin-to-creatinine ratio.](10.1177_2054358118813088-fig1){#fig1-2054358118813088}

Data Collection Methods {#section40-2054358118813088}
-----------------------

We will gather outcome measures 3 months and 6 months after randomization. To reduce the variability in the urinary albumin-to-creatinine ratio, we will take the mean of first morning urine samples collected on 2 consecutive days. In our previous work, we determined that the mean of two samples substantially reduced the standard deviation of the log-transformed percentage change from 0.59 to 0.49.^[@bibr28-2054358118813088]^ We will calculate the eGFR rates using the measured plasma creatinine concentrations. These will be measured at central hospital-based laboratories using standardized enzymatic colorimetric methods.

Nonadherence {#section41-2054358118813088}
------------

Patients who miss taking the investigational study medication over 7 or more days during any 4-week period will meet with an investigator to discuss ways of improving adherence. We will catalogue the reasons for nonadherence and the strategies used to overcome them. Patients who do not attend study visits will be contacted and encouraged to comply with the protocol in whatever way they can. Until the study ends or the participant withdraws consent, we will attempt to reach them 3 times within each 4-week period to determine their status. In extenuating circumstances, we will contact the patient's family physician to determine the patient's vital status.

Statistical Methods {#section42-2054358118813088}
-------------------

### Sample size {#section43-2054358118813088}

Most physicians would view a 15% to 25% reduction in albuminuria as evidence of a promising treatment effect. Such was the case for ACE inhibitors and angiotensin receptor blockers, which showed a reduction in albuminuria of 15% to 50% and were later proven to reduce the risk of mortality and ESRD.^[@bibr29-2054358118813088][@bibr30-2054358118813088][@bibr31-2054358118813088]-[@bibr32-2054358118813088]^ In our preliminary work on urinary albumin-to-creatinine ratio testing, we found patients eligible for MPAC-CKD-1 had a mean initial urinary albumin-to-creatinine ratio of 128.3 mg/mmol.^[@bibr28-2054358118813088]^ Over 3 months, we observed a mean increase in the urinary albumin-to-creatinine ratio of 30.7 mg/mmol and found the standard deviation of the change to be 69.2 mg/mmol. Using these data, enrolling 250 patients per group will allow an 87% power ($\underset{\cdot}{\alpha}$= 0.025) to exclude a difference of 21 mg/mmol. To allow for loss to follow-up, we expect to recruit up to an additional 75 patients to reach a minimum of 250 patients per arm with complete follow-up data. For changes in eGFR, we will have 90% power (α = 0.025) to exclude a difference of 2.3 mL/min/1.73 m^2^ between treatment and control groups (using a standard deviation of 4 mL/min/1.73 m^2^). This estimate is based on a reported average decline in eGFR in albuminuric CKD patients of 2 to 4 mL/min/1.73 m2/year (with a standard deviation of 3-4 mL/min/1.73 m^2^/year).^[@bibr33-2054358118813088],[@bibr34-2054358118813088]^

#### Primary outcome {#section44-2054358118813088}

We will conduct all primary analyses according to the intention-to-treat principle. Significance testing will be conducted with a two-sided alpha level of 0.05/2 using Hochberg adjustment for 2 simultaneous primary end points.^[@bibr35-2054358118813088]^ We will use two-sample *t* tests to compare changes in the co-primary outcomes.^[@bibr32-2054358118813088],[@bibr36-2054358118813088]^ Missing data will be handled using model-based multiple imputation methods (and sensitivity analyses will be performed to confirm that conclusions are not sensitive to assumptions about the missing-data mechanism)^[@bibr37-2054358118813088]^; the albumin-to-creatinine ratio data collected at the 3-month visit will be included in the imputation model.

#### Secondary outcomes {#section45-2054358118813088}

We will use a two-sample *t* test to compare changes in hemoglobin A1c between the 6-month and baseline values. The risk of the composite outcome of loss of ⩾30% of baseline eGFR, ESRD, or death will be compared between groups using logistic regression analysis. The proportions of patients discontinuing study capsules and experiencing adverse events will be compared between groups using the chi-square test.

#### Baseline characteristics {#section46-2054358118813088}

Randomization reliably removes random differences between treatment groups when at least 1000 participants are included.^[@bibr38-2054358118813088]^ With the size of our sample, it is possible that imbalances may arise between the treatment groups on important characteristics that may influence outcomes. We will record baseline characteristics pertinent to the progression of CKD and adjust the final point estimates of risk for these variables using linear regression analysis. Characteristics that will be included in the multivariable regression model are the following: age, sex, tobacco use, blood pressure, glycemic control, use of angiotensin-converting-enzyme inhibitors or angiotensin receptor blockers, use of aldosterone antagonists. Sodium-glucose co-transporter-2 (SGLT-2) inhibitors were approved for use in Canada in May 2014, and gained provincial formulary coverage in 2015. Because these medications have been shown to reduce albuminuria, we will record these use^[@bibr39-2054358118813088],[@bibr40-2054358118813088]^; however, given their minimum eGFR cut off of 45 mL/min/1.73 m^2^, we anticipate that they will not be commonly used in our population.

#### Other analyses {#section47-2054358118813088}

We will conduct an exploratory per-protocol analysis consisting of patients with no major protocol violations and who were exposed to their randomly assigned treatment for a minimum of 3 months. We will also conduct a subgroup analysis based on a higher or lower estimated risk of kidney failure (using the kidney failure risk equation).^[@bibr41-2054358118813088]^

Results {#section48-2054358118813088}
=======

MPAC-CKD-1 began enrollment on October 1, 2015, and has randomized 414 participants as of July 2018. We expect to complete enrollment in 2019 and report the results publicly in 2020.

Discussion {#section49-2054358118813088}
==========

Micro-particle curcumin holds a great deal of promise as a treatment to slow the progression of CKD because of its anti-inflammatory and anti-fibrotic properties.

*In vitro* experiments using a variety of cell lines have shown that curcumin exposure attenuates the activation of nuclear factor-kappa B (NF-κB). Activation of NF-κB is a pivotal regulatory step in the inflammatory process that leads to the elaboration of interleukin-1 (IL-1), IL-2, IL-6, tumor necrosis factor-alpha (TNF-α), and monocyte chemotactic protein-1 (MCP-1).^[@bibr42-2054358118813088]^ By blocking its activation, curcumin acts as a potent anti-inflammatory agent.^[@bibr43-2054358118813088][@bibr44-2054358118813088]-[@bibr45-2054358118813088]^ The conversion of functional tissue to scar is a hallmark of progressive CKD. Transforming growth factor-beta (TGF-β) is one of the most important mediators in this process.^[@bibr46-2054358118813088],[@bibr47-2054358118813088]^ In a variety of *in vitro* settings, curcumin has been shown to lessen the effect of TGF-β through inhibition of its molecular signaling,^[@bibr48-2054358118813088],[@bibr49-2054358118813088]^ activation of endogenous inhibitors,[@bibr50-2054358118813088] thereby resulting in less scar formation.^[@bibr51-2054358118813088],[@bibr52-2054358118813088]^

Animal models of CKD also support the effectiveness of curcumin exposure. Soetikno *et al* reported that compared with placebo, diabetic rats fed with curcumin 100 mg/kg per day for 8 weeks had far less scar tissue in their kidneys and expressed lower levels of TGF-β.[@bibr6-2054358118813088] In two related studies, Ghosh *et al* showed that rats with 5/6 nephrectomies who consumed 75 mg/kg curcumin per day had less proteinuria, better kidney function, more normal appearing renal histology, and lower levels of NF-κB and TNF-α than those on a placebo diet.[@bibr7-2054358118813088] Follow-up study of Ghosh et al showed that this benefit was realized even when curcumin treatment was delayed until after the appearance of proteinuria (a more clinically relevant timing of curcumin exposure).8 Sharma et al found similar effects in diabetic rats and demonstrated a dose-response.[@bibr9-2054358118813088]

Two small trials have tested curcumin supplementation in patients with kidney impairment.^[@bibr10-2054358118813088],[@bibr11-2054358118813088]^ In the study most applicable to MPAC-CKD-1, Khajehdehi et al randomized 40 patients with diabetic CKD to receive placebo or turmeric (0.5 g 3 times daily; approximately equivalent to 66 mg of curcumin per day) for 2 months. Both groups began the study with approximately 4.5 g of daily proteinuria. After only 2 months of treatment, the turmeric group had a 39% reduction in proteinuria while the placebo group's proteinuria remained unchanged.[@bibr10-2054358118813088] The treatment group experienced significant reductions in serum levels of TGF-β and TNF-α. In the second trial of patients with lupus nephritis, turmeric supplementation again decreased proteinuria significantly compared with placebo.[@bibr11-2054358118813088]

MPAC-CKD-1 is the next step in assessing micro-particle curcumin's potential to slow the progression of CKD. If meaningful changes in our surrogate outcome measure are observed, this will justify a larger, international trial equipped to test curcumin's ability to lower the risk of ESRD.

Supplemental Material {#section50-2054358118813088}
=====================

###### Supplementary_Materials -- Supplemental material for Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease-1: Study Protocol for a Multicenter Clinical Trial

###### 
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